Anpac Bio-Medical Science Company, Ltd., is led by award-winning and internationally respected biomedical and nanotechnology scientists, research and medical professionals, engineering experts and physicists — creating and launching break-through, leading edge, early cancer and other disease screening, detection, and diagnostic technology.
Anpac Bio’s “Cancer Differentiation Analysis” (CDA) liquid biopsy technology incorporates proprietary, in-vivo (or non-invasive) screening and diagnostics devices that measure simple, “Blood Biopsies” — assessing multiple microscopic parameters in whole blood samples, often identifying cancer pre-Stage One.
Comprehensive research validity data from over 80,000 cases to date indicate Anpac’s CDA screening and diagnostics far exceed existing or competing disease screening technologies – revealing a consistent sensitivity and specificity rate range of 70%-95% for over 26 different types of cancer to date. And it does so without any harmful side effects in patients; generating far fewer “false positives”; and at a cost substantially lower than traditional testing (such as imaging).
Anpac Bio-Medical is an international company promoting a corporate culture of creativity, teamwork, balance, and commitment to excellence, family, and social responsibility. For more information regarding Anpac Bio-Medical Science Company, please check: www.AnpacBio.com.
Company’s Keywords:
cancer, other disease detection, medical devices, screening, diagnostics, prognosis, biotechnology, nanotechnology, physics, engineering, biomedical science, reagents, testing, processing, data management, consulting
10
medical devices
3143000
Cloudflare DNS, Gmail, Google Apps, CloudFlare Hosting, Google Cloud Hosting, WP Engine, Typekit, Google Font API, New Relic, Google Tag Manager, Gravity Forms, WordPress.org, Mobile Friendly
2010